Rapid Diagnostic Supporting Antimicrobial Stewardship in Patients With Pneumonia

N/ACompletedNCT05937126

Mayo Clinic1,203 enrolled

Overview

The purpose of this study is to determine whether or not the FilmArray Penumonia Panel adds value to patient care.

Study Type

OBSERVATIONAL

Enrollment

1,203

Conditions

Lower Respiratory Tract Infections

Interventions

FilmArray Pneumonia PanelDIAGNOSTIC_TEST

FDA-approved/cleared molecular, multiplex device that rapidly identifies viruses, bacteria, and antimicrobial resistance genes in sputum-like and bronchoalveolar lavage (BAL)-like specimens obtained from individuals with signs of a lower respiratory tract infection.

Culture and antimicrobial susceptibility testingDIAGNOSTIC_TEST

Standard of care Gram stain, culture and other clinically ordered tests will be performed per standard practice.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Subjects who have the following samples collected and submitted for culture as part of routine clinical practice: Expectorated sputum, induced sputum, tracheal secretions, bronchoalveolar lavage. Exclusion Criteria: * Subjects who do not have MN Research Authorization on file * Rejected sputum culture (i.e., due to low quality) * Positive respiratory cultures within prior 7 days * Deceased at time of sample randomization * Any subject affected by Global Data protection Regulation (GDPR) * Previous enrollment in the study. * Outpatient status

Locations (1)

Mayo Clinic Minnesota

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Time until first modification of antibiotic therapy

Mean time until first modification of antibiotic therapy (in hours)

Time frame: 96 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.